Metronomic therapy from a pharmacologist's view

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 6, 2006, Pages 325-327

  Kamen, Barton A ^a   Glod, John ^a   Cole, Peter D ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; TEGAFUR; THALIDOMIDE; THROMBOSPONDIN;

ADVANCED CANCER; APOPTOSIS; CANCER CHEMOTHERAPY; CELL SURVIVAL; CELL TYPE; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; EWING SARCOMA; HUMAN; LETHAL DOSE; MAXIMUM TOLERATED DOSE; MEDLINE; METRONOMIC THERAPY; NOTE; NUCLEIC ACID SYNTHESIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TUMOR BLOOD FLOW;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHRONOTHERAPY; CLINICAL TRIALS, PHASE II; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL RATE; TIME FACTORS;

EID: 33745651419     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/00043426-200606000-00001     Document Type: Note

References (16)

1. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
2. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
3. Kieran MW, Turner C, Rubin J, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573-581.
4. Kamen BA. Metronomic therapy: it makes sense and is patient friendly. J Pediatr Hematol Oncol. 2005;27:571-572.
5. Marcus A. A new approach to chemotherapy. Wall Street Journal page D 1, October 25, 2005.
6. Shaked Y, Emmenegger U, Francia G, et al. Low-dose Metronomic combined with intermittent Bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;15:7045-7051.
7. Children's Oncology Group AEWS02P1. A Pilot Study of Low-dose Antiangiogenic Chemotherapy in Combination with Standard Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors A COG Groupwide Pilot.
8. Lam T, Hetherington JW, Greenman J, et al. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs. 2006;17:113-121.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
10. Damber JE, Vallbo C, Albertsson P, et al. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol. Epub ahead of print 1-7, 2005.
11. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006;66:3386-3391.
12. Tomoda R, Seto M, Hioki Y, et al. Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clin Exp Metastasis. 2005;22:559-564.
13. Kamen BA, Rubin E, Glatstein E, et al. High time chemotherapy or high time for low dose. J Clin Oncol. 2000;18:2935-2937.
14. Skipper HE, Schabel FM Jr, Mellett LB, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431-450.
15. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. March 16, Epub ahead of print, 2006.
16. Orzano JA, Swain SM. Concepts and clinical trials of dose-dense chemotherapy for breast cancer. Clin Breast Cancer. 2005;6:402-411.